This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
2026 Related Topics 
BioPharma Drive: Drug Pricing
OCTOBER 18, 2024
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.
265 
BioPharma Drive: Drug Pricing
OCTOBER 9, 2023
The purchase agreement with Chongqing Zhifei Biological Products is part of GSK’s plan to double sales of the shingles vaccine by 2026.
271
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Drive: Drug Pricing
JANUARY 30, 2025
head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker. Julie Kim, currently Takeda’s U.S.
164 
BioPharma Drive: Drug Pricing
MARCH 18, 2024
The funding could extend the cash-strapped gene therapy maker’s financial runway to 2026, but only if the company successfully hits certain milestones.
171 171 
BioPharma Drive: Drug Pricing
OCTOBER 24, 2024
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
139 
BioPharma Drive: Drug Pricing
OCTOBER 7, 2024
The company is committing to make at least 2 million doses of its long-acting PrEP therapy available in low- and middle-income countries next year and in 2026.
139 
BioPharma Drive: Drug Pricing
NOVEMBER 5, 2024
Rallybio is headed into a mid-stage trial with enough cash to last it through 2026, but biotech's down market has made the company's journey difficult.
130 
FDA Law Blog: Biosimilars
MARCH 19, 2024
Hyman, Phelps & McNamara, P.C. (HP&M), HP&M), the largest dedicated food and drug law firm in the U.S., is pleased to announce that Director Allyson Mullen has been appointed to the Board of Directors of the Association of Medical Diagnostic Manufacturers (AMDM). This prestigious appointment recognizes Ms.
59 
FDA Law Blog: Biosimilars
MARCH 5, 2024
AstraZeneca also claimed that CMS’s revised guidance on the Negotiation Program for Price Applicability Year 2026 (“Guidance”) interpreted the IRA in two very faulty ways, which violated the Administrative Procedure Act (APA) and harmed and will continue to harm the company. The court found numerous flaws with this argument.
64 
Agency IQ
MARCH 25, 2024
BY SCOTT STEPHENS, MPA This week, ECHA finalized its annual update to the Community Rolling Action Plan (CoRAP), listing 28 substances that will be assessed under the REACH Regulation’s substance evaluation procedure during the 2024-2026 period.
59 
PPD
OCTOBER 31, 2024
Small/mid-size participants in particular indicate greater use of DCTs, expecting higher use by 2026. As DCTs become standard across toolkits, there is greater opportunity to implement decentralized approaches when needed.
FDA Law Blog: Biosimilars
SEPTEMBER 16, 2024
Regarding CDER’s ETP, the current ETP guidance document, originally published in 2017, will be updated by the end of 2026, and will include details on communicating the type of products and stages of development for which a requestor can approach the ETP.
59 
Perficient: Drug Development
MAY 30, 2024
.” – Marybeth Wrabel How We’re Approaching Transformation, Modernization, and Mandates There’s plenty of discussion and investment happening already among insurers, as they address interoperability and prepare for a Prior Authorization mandate in 2026.
88 
The Pharma Data
SEPTEMBER 27, 2021
7.125% Notes due 2025 532457 AM0 3 0.750% due August 31, 2026 0.820% 15 bps $1,222.65 5.500% Notes due 2027 532457 AZ1 7 0.750% due August 31, 2026 0.820% 40 bps $1,226.23 3.100% Notes due 2027 532457 BP2 13 0.750% due August 31, 2026 0.820% 35 bps $1,100.66
52 
Perficient: Drug Development
AUGUST 22, 2023
According to Gartner’s 2022 Industry Cloud Survey , about 40% of IT leaders say they have started to adopt industry cloud platforms, with another 15% in pilots; another 15% are considering deployment by 2026. One of the ways healthcare and life sciences organizations are moving to the cloud is by adopting digital health platforms (DHP).
98 
Drug Channels
SEPTEMBER 25, 2024
ET on the following dates: April 4, 2025 June 20, 2025 December 12, 2025 (Drug Channels Outlook 2026) For 2025, we are offering a Corporate Pricing option that will allow larger organizations to register hundreds of colleagues for one fixed price. The three events are scheduled for 12:00 p.m. to 1:30 p.m.
52 
FDA Law Blog: Biosimilars
JUNE 26, 2023
September 1, 2023 will be the selection date for the 10 drugs that will be subject to “maximum fair price” ceilings under Medicare Part D starting in 2026. Chamber of Commerce makes all the arguments that the other plaintiffs have made, and also alleges that Congress has no power to levy the excise tax because it “compels” commerce.
The Pharma Data
JULY 6, 2021
Adjusted operating margins are expected to improve from the current mid-20s level to over 30% by 2026. Cash generated from operations is expected to exceed £10 billion by 2026. 2021-2026 outlook refers to the 5 years to 2026 with 2021 as the base year.
52 
Agency IQ
MARCH 25, 2024
ECHA flags 28 substances for evaluation over next three years This week, ECHA finalized its annual update to the Community Rolling Action Plan (CoRAP), listing 28 substances that will be assessed under the REACH Regulation’s substance evaluation procedure during the 2024-2026 period.
40 
The Premier Consulting Blog
APRIL 27, 2023
How can you prepare?
52 
Agency IQ
JULY 22, 2024
According to that version of the plan, the actor and market surveillance modules would be complete as of Q4 2023, the certificates module by Q1 2024, the device and vigilance modules by the end of Q2 2024, and the CI/PS module estimated to be ready for Q3 2026. The announcement that the vigilance module is ready is projected for January 2026.
40 
Broad Institute
OCTOBER 24, 2024
The GEDMex team — comprising researchers, clinicians, project managers, and others at Harvard, the Broad Institute, INPRFM, and participating institutions — aims to collect and genetically analyze samples from 6,000 people with eating disorders and 3,000 controls by 2026.
52 52 
FDA Law Blog: Biosimilars
DECEMBER 3, 2023
On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. The Discount Program is similar to the CGDP with respect to several requirements and operational processes, and CMS will implement it in a similar manner.
105 
Drug Target Review
JULY 4, 2023
The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. 1 Regulators invest significant consideration balancing quality-of-life measures with overall survival when assessing novel oncology treatments.
145 
Common Sense for Drug Policy Blog
JUNE 10, 2023
At the time of writing, the City of San Francisco funds naloxone distribution in seven of its approximately 75 supportive housing SROS, and has committed to making naloxone available in all its supportive housing facilities by 2026 ( San Francisco Department of Public Health 2022 ; Thadani & Palomino, 2022 ). 2017 ; Rowe et al.,
The Pharma Data
OCTOBER 31, 2020
billion USD by 2026 at a CAGR of 11.5%. With the IND approval in place, we are ready and eager to extend the clinical study of TG-1000 to the U.S. in the near future.” ” According to Global Data, the global market for influenza antivirals reached 2.34 billion USD in 2019 and is estimated to reach 5.03
52 
National Institute on Drug Abuse: Nora's Blog
NOVEMBER 4, 2024
Participants will meet virtually three or four times during 2025 and potentially early 2026 and will be compensated for their time during the meetings. For that group, we are seeking individuals who identify as having experience with substance use or a substance use disorder or as a family or caregiver of someone who does.
85 
Broad Institute
OCTOBER 25, 2024
El equipo del GEDMex cuenta con investigadores, clínicos, coordinadores de proyectos y otros profesionales del INPRFM, Harvard, el Instituto Broad y las instituciones participantes, y tiene como objetivo recoger y analizar genéticamente muestras de 6.000 persons con trastornos de la conducta alimentaria y 3.000 controles hasta el 2026.
52 
FDA Law Blog: Biosimilars
JUNE 14, 2023
In FY 2026 – FY 2027, continue to support products enrolled in previous fiscal years and expand to enroll up to 100 additional products each fiscal year within existing OHTs or expand to additional OHTs, depending on lessons learned from FY 2023 – FY 2025 experience (i.e., up to 125 total products enrolled through FY 2025).
45 
The Pharma Data
SEPTEMBER 7, 2021
0.750% due August 31, 2026. 0.750% due August 31, 2026. 0.750% due August 31, 2026. 0.750% due August 31, 2026. 3.950% Notes due 2049. 532457 BT4. 1,500,000,000. 2.375% due May 15, 2051. 7.125% Notes due 2025. 532457 AM0. 229,692,000. 6.770% Notes due 2036. 532457 AP3. 174,445,000. 1.250% due August 15, 2031. 532457 BC1.
52 
Advarra
AUGUST 8, 2024
While some of the AI Act’s compliance dates are set for August 2024, the full Act will be enforced in March 2026. Unacceptable risk AI systems are banned outright, while high-risk systems must comply with stringent requirements, including transparency, data governance, registration with the central competent authorities, and human oversight.
Drug Target Review
JANUARY 4, 2024
Then it’s on to dosing and administration studies in animals, pivotal toxicology studies, and, following a successful funding round, first-in-human studies in 2026. We’ve made great progress to date and have every faith that the program will continue to progress with remarkable promise.
98 
FDA Law Blog: Biosimilars
FEBRUARY 21, 2024
One of the major changes is the extension of the transition period from one to two years, with FDA now planning to enforce the QMSR requirements upon the effective date of the final rule on February 2, 2026.
59 
LifeSciVC
APRIL 2, 2024
We have milestones on the horizon, and we want investors to stay close to the Sionna story even if we don’t need capital until 2026. As an example of the continued engagement, we headed to the TD Cowen healthcare conference in early March before the ink was dry on the Series C closing.
69 
The Pharma Data
DECEMBER 8, 2020
Ionis projects having the opportunity to launch six or more new products through 2026, with each being ready for launch in a close window, ranging from 18 to 24 months between each new product launch. The expectation is that the implementation of this strategy will drive double-digit revenue growth and substantial earnings growth. .
52 
Alta Sciences
JANUARY 31, 2025
Ria is currently an industry member of the STCs Scientific Program Committee and will serve in this role until 2026, after which she will transition to Committee Chair until 2027. She also contributed extensively to quality assurance and study design processes, fostering collaboration and consistency across teams.
52 
Perficient: Drug Development
DECEMBER 27, 2023
The effective date of the new rule is April 1, 2024, with key provisions taking effect on January 1, 2026, and January 1, 2027. Banks Additionally, the recent rule by the OCC, the Federal Reserve, and the FDIC strengthens and modernizes Community Reinvestment Act (CRA) regulations.
52 
FDA Law Blog: Biosimilars
OCTOBER 12, 2023
Priority is given to Suitability Petitions that could mitigate or resolve a drug shortage; address a public health emergency declared by HHS; mitigate waste by way of new strengths for parenteral products; or subject to special review under the President’s Emergency Plan for Aids Relief.
59 
The Pharma Data
MARCH 31, 2022
million patients, provided with essential medicines by the global health unit, for the treatment of non-communicable diseases in 40 of the world’s poorest countries, between 2022 and 2026. The coupon amounts are linked to the achievement of a sustainability performance target defined as the cumulative number of patients, being at least 1.5
52 
FDA Law Blog: Biosimilars
SEPTEMBER 22, 2024
Complaints FDA discussed how LDT developers should handle the transition from the current Quality System Regulation (QSR)(21 CFR Part 820) to the recently promulgated Quality Management System Regulation (QMSR) that is scheduled to take effect on February 2, 2026.
64 
The Pharma Data
APRIL 14, 2021
The five-year project will see the site fully operational in Q1 2026 once all qualifications and validations of the first manufactured vaccine have been completed. The project is currently entering its design phase with construction expected to begin in Q3 2021.
52 
The Pharma Data
APRIL 29, 2022
The site, scheduled for completion in 2026, will be in close proximity to several major academic, pharma and biotech institutions, inspiring greater collaboration and innovation potential, and providing access to future talent.
40 
Perficient: Drug Development
OCTOBER 15, 2024
A recent study from IDC suggests that by 2026, 70% of financial institutions will have formalized data governance frameworks in place. With the rise of AI, machine learning, and real-time data analytics, banks will need to be even more diligent in how they manage and govern their data.
52 
FDA Law Blog: Biosimilars
OCTOBER 4, 2023
Note that Astellas withdrew its lawsuit after none of its drugs were selected for price reduction in 2026—potentially because that fact cut against its argument for standing. Harm The Court reviewed the parties’ arguments on “irreparable harm to Plaintiffs.”
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content